Skip to main content

Table 1 Clinicopathologic variables and the expression of FAM83H and Nectin1 in bladder urothelial carcinomas

From: FAM83H and Nectin1 expression are related with survival and relapse of bladder urothelial carcinoma patients

Characteristics Total FAM83H expression p Nectin1 expression p Combined expression p
Positive Negative Positive Negative FAM83H+/Nectin1+ FAM83H+/Nectin1− or FAM83H−/Nectin1+ FAM83H−/Nectin1−
All cases 165 110 (66.7%) 55 (33.3%)   101 (61.2%) 64 (38.8%)   86 (52.1%) 39 (23.6%) 40 (24.2%)  
Sex Male 145 96 (66.2%) 49 (33.8%)   87 (60%) 58 (40%)   74 (51%) 35 (24.1%) 36 (24.8%)  
  Female 20 14 (70%) 6 (30%) 0.736 14 (70%) 6 (30%) 0.39 12 (60%) 4 (20%) 4 (20%) 0.753
Age (years) ≤ 65 44 25 (56.8%) 19 (43.2%)   25 (56.8%) 19 (43.2%)   20 (45.5%) 10 (22.7%) 14 (31.8%)  
  > 65 121 85 (70.2%) 36 (29.8%) 0.106 76 (62.8%) 45 (37.2%) 0.485 66 (54.5%) 29 (24%) 26 (21.5%) 0.377
Histologic grade Low 56 23 (41.1%) 33 (58.9%)   21 (37.5%) 35 (62.5%)   14 (25%) 16 (28.6%) 26 (46.4%)  
  High 109 87 (79.8%) 22 (20.2%)  < 0.001 80 (73.4%) 29 (26.6%)  < 0.001 72 (66.1%) 23 (21.1%) 14 (12.8%)  < 0.001
T stage Ta 37 18 (48.6%) 19 (51.4%)   19 (51.4%) 18 (48.6%)   12 (32.4%) 13 (35.1%) 12 (32.4%)  
  T1 77 50 (64.9%) 27 (35.1%)   46 (59.7%) 31 (40.3%)   39 (50.6%) 18 (23.4%) 20 (26%)  
  T2-4 51 42 (82.4%) 9 (17.6%) 0.004 36 (70.6%) 15 (29.4%) 0.176 35 (68.6%) 8 (15.7%) 8 (15.7%) 0.021
N stage N0 158 104 (65.8%) 54 (34.2%)   94 (59.5%) 64 (40.5%)   80 (50.6%) 38 (24.1%) 40 (25.3%)  
  N1-3 7 6 (85.7%) 1 (14.3%) 0.275 7 (100%) 0 (0%) 0.031 6 (85.7%) 1 (14.3%) 0 (0%) 0.163
M stage M0 160 105 (65.6%) 55 (34.4%)   97 (60.6%) 63 (39.4%)   82 (51.3%) 38 (23.8%) 40 (25%)  
  M1 5 5 (100%) 0 (0%) 0.108 4 (80%) 1 (20%) 0.381 4 (80%) 1 (20%) 0 (0%) 0.359
TNM stage Stage 0 37 18 (48.6%) 19 (51.4%)   19 (51.4%) 18 (48.6%)   12 (32.4%) 13 (35.1%) 12 (32.4%)  
  Stage I 77 50 (64.9%) 27 (35.1%)   46 (59.7%) 31 (40.3%)   39 (50.6%) 18 (23.4%) 20 (26%)  
  Stage II, III 46 37 (80.4%) 9 (19.6%)   32 (69.6%) 14 (30.4%)   31 (67.4%) 7 (15.2%) 8 (17.4%)  
  Stage IV 5 5 (100%) 0 (0%) 0.008 4 (80%) 1 (20%) 0.298 4 (80%) 1 (20%) 0 (0%) 0.056
Recurrence Present 49 39 (79.6%) 10 (20.4%)   37 (75.5%) 12 (24.5%)   30 (61.2%) 16 (32.7%) 3 (6.1%)  
  Absent 116 71 (61.2%) 45 (38.8%) 0.022 64 (55.2%) 52 (44.8%) 0.014 56 (48.3%) 23 (19.8%) 37 (31.9%) 0.002